STOCKS TELEGRAPH

Category: Mid Day Movers

  • Arrive AI (ARAI) Sees Strong Market Momentum Following Patent Milestone

    Arrive AI (ARAI) Sees Strong Market Momentum Following Patent Milestone

    Following the news of a newly awarded U.S. patent, Arrive AI Inc. (NASDAQ: ARAI) shares are experiencing a 120.22% increase on the charts to $13.94 in recent trade. The move highlights ARAI’s expanding presence in the autonomous logistics space, especially with Arrive Points, its AI-powered smart mailbox platform.

    Healthcare Applications Drive Innovation

    The latest patent, now the eighth granted in the U.S. to Arrive AI (ARAI), introduces advanced climate control capabilities for the smart mailbox system, allowing items to be heated or cooled as needed. With six additional patents still pending, the company is strengthening its intellectual property portfolio in the high-tech delivery space.

    Revolutionizing Package Delivery

    This new feature is especially helpful for industries like healthcare that need to regulate temperatures strictly. Sensitive items, such as medications and tissue samples, are intended to be stored in the smart mailbox at precise temperatures, guaranteeing their safety and integrity when they are received. In addition to offering more customer convenience, this innovation has the potential to greatly benefit pharmacies, hospitals, and labs.

    The patent also includes a host of cutting-edge features: temperature preservation pre- and post-delivery, explosive material detection, ultraviolet and ozone sterilization, battery charging and exchange capabilities, facial recognition for both humans and pets, weather monitoring, and integrated communications systems including LED alerts and two-way speakers.

    Strategic Vision and Market Leadership

    Dan O’Toole, CEO of Arrive AI, initially conceptualized the smart mailbox system for retail and food delivery. He filed for the foundational patent in 2014—just four days ahead of Amazon—and secured it in 2017. His foresight positioned the company as an early innovator in autonomous delivery technology.

    Global Expansion and Technological Depth

    In addition to the newly secured patent, Arrive AI holds U.S. patents covering drone management, anti-theft technology, and intelligent chain-of-custody systems. With 58 patents pending across 22 countries and several trademarks in place, ARAI is aggressively expanding its reach and technological capabilities. These developments signal that Arrive Points are evolving into a comprehensive logistics infrastructure, poised to transform autonomous delivery on a global scale.

  • Klotho Neurosciences (KLTO) Soars In Pre-Market Session

    Klotho Neurosciences (KLTO) Soars In Pre-Market Session

    In pre-market trading, Klotho Neurosciences, Inc. (NASDAQ: KLTO) increased 63.19% to $2.97, continuing its strong upward trend in the stock market. This comes after shares finished at $1.82 in the previous session, a startling 787.80% increase. The revelation of promising pre-clinical data pertaining to the Klotho gene and gene replacement treatment is credited with the spike.

    Innovation in Aging Gene Therapy

    The new results are based on research that showed a decrease in age-related deterioration in several organs by increasing the expression of the Klotho gene. This finding raises the possibility of greatly increasing longevity and healthspan.

    Professor Makoto Kuro-O’s seminal work from 1997, which connected decreased blood levels of the Klotho protein to shorter animal lifespans, served as the basis for this study. Additionally, his group demonstrated that mice that were genetically altered to overexpress Klotho had 30% to 40% longer lifespans than their typical counterparts.

    Klotho Protein Secreted Has Therapeutic Potential

    The effects of the secretory Klotho protein variation (s-KL) on both healthy aging mice and those with accelerated aging characteristics were investigated in a recent study headed by Joan Roig-Soriano and colleagues and published in the February 2025 issue of Molecular Therapy. The s-KL therapy, which was given using an adeno-associated viral vector (AAV9), considerably raised blood protein levels and resulted in a 20% increase in lifetime.

    The study confirmed s-KL’s potential as a therapeutic molecule against aging-related deterioration by identifying several biological pathways as being positively effected by it, including those linked to cell stress, inflammation, and tissue repair.

    Exclusive Global Licensing and Future Focus

    The unique global license for s-KL is held by Klotho Neurosciences (KLTO) from the Institució Catalana de Recerca i Estudis Avançats (ICREA) and the Universitat Autònoma de Barcelona (UAB). These rights cover the therapeutic use of the s-KL variant in the treatment of age-related and neurodegenerative diseases and are applicable in the United States, Europe, and China.

    Notably, Professor Kuro-O serves as a scientific advisor to KLTO. The company is now directing its efforts toward developing s-KL therapies for conditions such as ALS, Alzheimer’s, and Parkinson’s disease.

  • Jade Biosciences (JBIO) Rallies In After-Hour Trading

    Jade Biosciences (JBIO) Rallies In After-Hour Trading

    On Monday, there was significant market momentum for Jade Biosciences, Inc. (NASDAQ: JBIO), as shares increased 7.23% during regular trading to finish at $7.71 and then 5.32% during after-hours trading to hit $8.12.

    The company’s recent scientific presentation at the 62nd European Renal Association (ERA) Congress, where it revealed promising preclinical results for JADE101, its primary therapy option for IgA nephropathy (IgAN), was a major factor in the JBIO stock spike.

    Scientific Discovery Addressing a Serious Unmet Need

    Inhibiting APRIL (A Proliferation-Inducing Ligand), a crucial component in the development of IgAN, an autoimmune kidney disease usually identified in early adulthood, is the goal of the completely human monoclonal antibody JADE101.

    Due to their limited effectiveness and difficulties with patient adherence, current IgAN therapy options frequently fall short. According to research from Jade Biosciences, JADE101 may provide a disease-modifying treatment that is best in class, requires little dosage, and has long-lasting therapeutic benefits.

    Superior Molecular Structure with Elevated Binding Affinity

    Jade Biosciences described the structural benefits of JADE101 in their oral presentation at ERA. The IgG1 backbone of the antibody has been altered by YTE, which improves pharmacokinetics and prolongs systemic exposure.

    Long dosage intervals—possibly every eight weeks or longer—are supported by this strategy while preserving strong target engagement. Notably, JADE101 binds APRIL with femtomolar affinity (~50 fM), over 750 times higher than sibeprenlimab, a first-generation competitor.

    Minimizing Risks, Maximizing Consistency

    JADE101 also addresses key safety and stability issues faced by earlier anti-APRIL agents. By avoiding the formation of large molecular weight immune complexes—which are frequently linked to immunogenicity, tissue deposition, and quick drug clearance—it targets a unique epitope on trimeric APRIL. The compound may offer longer therapeutic exposure and more consistent pharmacokinetic profiles by avoiding these problems.

    Subsequent Actions for Clinical Trials

    In the second half of 2025, Jade Biosciences (JBIO) hopes to begin a healthy volunteer trial for JADE101. In addition to biomarker suppression, the study will evaluate pharmacokinetics, pharmacodynamics, safety, and tolerability. Interim results are expected in early 2026 and will inform dose selection for future studies involving patients with IgAN.

  • After-Hour Session Boosts BioSig (BSGM) Amid Leadership News

    After-Hour Session Boosts BioSig (BSGM) Amid Leadership News

    After-hours trading on Monday saw a slight recovery for BioSig Technologies, Inc. (NASDAQ: BSGM), with shares closing at $6.64, up 5.40%. Following a steep 14.05% drop during regular trading, which saw the stock close at $6.30, this occurred. Following a noteworthy statement about important strategic appointments meant to fortify the company’s strategy in asset tokenization and decentralized finance, the recovery took place.

    Industry Innovators Join as Strategic Advisors

    BioSig Technologies (BSGM), which recently acquired Streamex Exchange Corporation as a wholly owned subsidiary, revealed the appointment of Trevor Bacon and Kellan Grenier as Strategic Advisors. Both are co-founders of Parcl, a pioneering blockchain-native platform that offers synthetic exposure to real estate markets without the need for direct property ownership.

    Operating on the Solana blockchain, Parcl enables users to speculate on real estate price trends across major cities through perpetual trading. Bacon, currently CEO of Parcl, brings over ten years of experience in finance, with prior roles at Barclays and multiple hedge funds, where he focused on investments in technology and digital payments.

    Grenier, the platform’s COO, adds his background as a long/short equity analyst in the TMT sector, with a strong emphasis on blockchain strategy, tokenomics, and partnership development.

    Driving Innovation in Real-World Asset Tokenization

    The addition of Bacon and Grenier is seen as a strategic move to position BioSig Technologies and Streamex at the forefront of real-world asset tokenization—particularly in complex, illiquid markets. Their leadership in building decentralized trading protocols is expected to be pivotal as the company scales its digital infrastructure and explores opportunities in synthetic asset creation and financial innovation.

    Sean Roosen Brings Commodities Expertise

    Complementing this vision, BioSig Technologies last week also named Sean Roosen as Strategic Advisor to Streamex. Roosen, a renowned mining executive and financier, brings more than 30 years of experience building multibillion-dollar resource ventures. He currently serves as Founder, Executive Chairman, and CEO of Osisko Development Corp., and previously led Osisko Gold Royalties.

    His deep expertise in the commodities sector is anticipated to accelerate Streamex’s entry into tokenized commodities, reinforcing BSGM’s ambition to lead in digital finance and asset-backed trading solutions.

  • Synaptogenix (SNPX) Stock Climbs Following Treasury Strategy Shift

    Synaptogenix (SNPX) Stock Climbs Following Treasury Strategy Shift

    Synaptogenix, Inc. (NASDAQ: SNPX) witnessed a remarkable upswing in its stock performance, with shares rising by 52.70% to $3.68 at last check. The surge follows the company’s announcement of a novel cryptocurrency-based treasury strategy. At the heart of this move is a targeted investment in TAO, the leading artificial intelligence (AI) cryptocurrency token by market capitalization and adoption.

    Strategic Focus on TAO Token Acquisition

    Synaptogenix plans an initial acquisition of $10 million worth of TAO tokens, a value exceeding twice the company’s current market capitalization. This bold strategy is a component of a larger plan to eventually amass up to $100 million in TAO tokens.

    The initial funding will be sourced from the company’s robust cash reserves and well-capitalized balance sheet. The move reflects the board’s late-2024 strategic pivot to unlock shareholder value through digital asset integration—a trend increasingly seen across both public and private sectors.

    Leadership and Industry Alignment

    James Altucher, a well-known businessman and expert in AI and crypto, has been named to head Synaptogenix’s TAO-focused revenue plan. Altucher, an early advocate of Bitcoin and a published AI researcher, brings extensive experience in emerging technologies.

    He will spearhead initiatives involving TAO staking and token appreciation, aiming to maximize returns for shareholders. TAO, the native currency of the decentralized Bittensor blockchain, is seen by Synaptogenix as a prime asset due to its fixed supply of 21 million tokens and rising demand driven by global AI adoption.

    Corporate Rebranding and Financing Measures

    Details of SNPX’s planned rebranding, which will include a new name, ticker symbol, and website, will be made public in the upcoming months in order to better match with its strategic goal.

    A $5.5 million private placement financing deal including the issuing of Series D convertible preferred stock and warrants, both priced at $3.00 per share, was also disclosed by Synaptogenix (SNPX) at the same time. Under normal circumstances, the financing—in which Altucher is a participant—should close by June 10, 2025.

  • Market Responds Positively To Phio Pharmaceuticals’ Strategic Direction

    Market Responds Positively To Phio Pharmaceuticals’ Strategic Direction

    The clinical-stage biopharmaceutical company Phio Pharmaceuticals Corp. (NASDAQ: PHIO), which specializes in siRNA-based cancer treatments, saw a sharp rise in stock value after launching a new strategic strategy. As of the latest transaction data, PHIO shares were up 7.42% to $3.18, reflecting investor confidence in the company’s growing emphasis.

    Increasing the Therapeutic Potential of INTASYL

    The business is developing its in-house INTASYL gene silencing technology, which consists of a pipeline of about 30 chemicals at the moment. With its recently revealed strategic plan, Phio hopes to raise awareness of the portfolio’s wider applications.

    This action comes after the current Phase 1b dosage escalation study of PH-762, an INTASYL chemical used to treat skin cancer, showed encouraging interim safety and effectiveness results. Preclinical and clinical evidence suggest that INTASYL may find application in a broader number of therapeutic domains.

    Change in Leadership to Promote Development

    Phio announced significant leadership changes that would take effect on June 9, 2025, in support of these goals. Former Chief Financial Officer Mr. Robert Infarinato has been promoted to Vice President of Strategic Development. Mr. Infarinato will spearhead business development initiatives aimed at extending the INTASYL platform’s strategic reach in his new position.

    With more than thirty years of expertise in operations and finance, Mr. Infarinato has held high-level roles such as Chairman of the Board of Trustees of Abington Health and Executive Vice President and CFO of a global services organization.

    Strengthened Finance Leadership

    Ms. Lisa Carson was appointed Vice President of Finance and Administration at the same time. With more than 20 years of experience in finance leadership, Carson joined Phio in May 2025.

    She previously served as Controller and Vice President of Finance at Prelude Therapeutics being  a key player in the IPO and growth of the business over time. Moreover, her previous roles at TELA Bio and PhaseBio Pharmaceuticals attest to her expertise in biopharma finance operations.

    These key hires demonstrate Phio’s dedication to developing its cutting-edge siRNA technology and increasing shareholder value via focused research and strengthened leadership.

  • After-Hour Trading Lifts Algorhythm (RIME) Shares On Expansion News

    After-Hour Trading Lifts Algorhythm (RIME) Shares On Expansion News

    Algorhythm Holdings, Inc. (NASDAQ: RIME) shares saw a notable recovery in after-hours trading last Friday, gaining 10.80% to close at $2.77. This rebound offset a 6.72% loss earlier in the regular trading session, which had seen RIME stock finish at $2.50. The positive momentum followed news of a major expansion initiative in India through its subsidiary, SMCB Solutions Private Limited, also known as SemiCab India.

    Major Contract Expansion with Global CPG Leader

    Algorhythm (RIME) recently announced that SemiCab India had secured a substantial extension to its Master Services Agreement with the Indian subsidiary of the world’s third-largest consumer packaged goods (CPG) manufacturer, a company boasting annual revenues exceeding $84 billion.

    The first phase of the expansion involves SemiCab India providing managed transportation services across more than 40 high-density routes throughout India—a 200% increase in its current lane coverage. Upon successful implementation, the CPG giant plans to further expand both the geographical footprint and number of serviced lanes.

    Introducing “Drop & Hook” Freight Operations in India

    In conjunction with the expanded agreement, Algorhythm-subsidiary will launch a new pilot program introducing the “drop and hook” freight model, widely used in the United States. By allowing drivers to switch out fully loaded trailers for ones that are already loaded, this technology significantly cuts down on loading and unloading downtime.

    Due to logistical and infrastructure obstacles, the concept has not been widely adopted in India, despite its success outside. With a potential 80% turnaround time reduction and the ability to increase truck mileage from 3,200 to 5,000 miles per month—all with little additional operating costs—Semicab’s unique Collaborative Transportation Platform, on the other hand, is well-positioned to overcome these obstacles.

    Strategic Positioning in a Competitive Market

    In addition to increasing shipment efficiency, this creative strategy offers Algorhythm a clear competitive advantage in the Indian logistics market. With the platform going live in June 2025, SemiCab India is poised to transform the freight landscape. Maintaining a fully deployed fleet while meeting unmatched service metrics positions RIME for accelerated growth and a robust foothold in one of the world’s fastest-growing markets.

  • After-Hour Session Sees Tempest Therapeutics (TPST) Shares Soar

    After-Hour Session Sees Tempest Therapeutics (TPST) Shares Soar

    Tempest Therapeutics, Inc. (NASDAQ: TPST) had a 48.58% increase in share price last Friday after hours, closing at $12.25. TPST shares surged when the European Medicines Agency (EMA) announced that the company’s investigational medication, amezalpat (TPST-1120), had been granted Orphan Drug Designation (ODD).

    Movement Gains Strength in the US and Europe

    This further classification from the EMA has already been backed by the U.S. Food and Drug Administration (FDA), which has already given amezalpat both Orphan Drug and Fast Track status.

    TPST-1120 can be used to treat hepatocellular carcinoma (HCC), a kind of liver cancer. Amezealpat is an oral selective PPAR⍺ antagonist that targets tumor cells and modifies immune responses.

    Tempest Therapeutics’ believe in amezalpat’s therapeutic potential is strengthened by these regulatory recognitions, which also highlight the significant unmet medical need in liver cancer.

    Clinical Data Emphasizes the Advantage of Survival

    The designations resulted from positive results from a global, randomized Phase 1b/2 clinical study that compared amezalpat with standard therapies—atezolizumab and bevacizumab—versus the standard treatment alone.

    Patients receiving the amezalpat regimen demonstrated a six-month extension in median overall survival, with a hazard ratio of 0.65. Importantly, the therapy also showed consistent benefit in patients with PD-L1 negative disease, supporting its dual mechanism of action.

    Expanded Research and Strategic Plans

    Further validation of amezalpat’s immune-modulatory effects was presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, underscoring its potential as an innovative cancer therapy.

    Additionally, the FDA has issued a “Study May Proceed” letter for a Phase 2 trial involving amezalpat for familial adenomatous polyposis (FAP), led by CP-CTNet and funded by the National Cancer Institute. The research is scheduled to start in 2025.

    As part of its efforts to streamline operations and increase shareholder value, Tempest Therapeutics (TPST) also confirmed a headcount reduction that was finished on April 30, 2025, and announced a strategic evaluation of its clinical-stage initiatives to complement its expanding portfolio.

  • Venus Concept (VERO) Stock Gains Momentum After Strategic Asset Sale

    Venus Concept (VERO) Stock Gains Momentum After Strategic Asset Sale

    The news of a strategic asset sale caused Venus Concept Inc. (NASDAQ: VERO) to see a sharp increase in the value of its shares. At $3.57, shares of VERO had experienced a remarkable 49.37% rise as of the most recent market check.

    Strategic Diversification Increases Market Trust

    Following a definitive agreement to sell its Venus Hair division to MHG Co. Ltd., commonly known as Meta Healthcare Group, for $20 million in total cash, subject to standard working capital adjustments, the momentum has been building.

    It is anticipated that the transaction’s net proceeds would strengthen Venus Concept’s balance sheet and supply vital capital for upcoming key expansion projects. The company’s larger analysis of strategic options with the goal of optimizing shareholder value includes this divestment.

    Venus Concept intends to simplify operations and focus on its primary medical aesthetics business by selling off the Venus Hair division. The action is expected to boost long-term profitability, lower operating costs, and increase revenue.

    Increasing Share in Hair Restoration Market

    Through the acquisition, Meta Healthcare Group will secure ownership of Meta Robotics LLC, a newly formed subsidiary of Venus Concept. This includes the complete portfolio of hair restoration and transplant technologies—ARTAS and NeoGraft—as well as associated intellectual property, equipment, and service infrastructure.

    These technologies are recognized for their strong market presence across Asia, Europe, and North America, supported by loyal customer bases and brand recognition.

    Future Collaboration and Operational Continuity

    As part of the agreement, Meta Healthcare Group will grant Venus Concept a perpetual, royalty-free, worldwide license to a subset of the transferred patents. Additionally, MHG will acquire the production rights for NeoGraft as well as Venus VERO’s manufacturing and R&D facilities in San Jose, California.

    The third quarter of 2025 is when the deal is expected to conclude. Venus Concept (VERO) affirmed that it will keep looking for strategic options to increase the company’s long-term worth in spite of the transaction.

  • SatixFy (SATX) Shares Climb After Amended Merger Agreement

    SatixFy (SATX) Shares Climb After Amended Merger Agreement

    After SatixFy Communications Ltd. (NYSE: SATX) revealed a major change to its previously disclosed merger agreement with MDA Space Ltd. (TSX: MDA) on April 1, 2025, the company’s shares shot up 43.38%, trading at $2.93 as of the last check. The revised terms enhance the value of the all-cash transaction, increasing the per-share offer and total company valuation.

    Revised Terms Reflect Competitive Offer

    A new equity valuation of over $280 million, a significant increase from the original $193 million, will result from MDA Space’s acquisition of SatixFy for $3.00 per ordinary share under the amended merger agreement, up from the previous offer of $2.10.

    Following a thorough “go-shop” procedure in which around 75 third parties were approached to gauge their interest in purchasing the business, SatixFy made this change with the advising assistance of TD Securities (USA) LLC.

    A third party made an alternate purchase offer to SatixFy during this process, offering a stock-based deal for around $233.5 million, or $2.53 per share. SatixFy and MDA continued to negotiate as a result of this competitive offer, which led to the increased financial consideration.

    Board Choice and Support from Shareholders

    The Board of Directors of SatixFy determined that the all-cash deal at $3.00 per share offered the best result for shareholders after considering the updated proposal. Their assessment took into account a number of variables, such as timing, transaction certainty, and the overall operational and financial environment.

    SatixFy has pledged to renounce any further acquisition talks and uphold its support for the MDA merger as part of the updated agreement. Voting support agreements have already been signed by about 57% of SatixFy’s shareholders, indicating their support for the deal.

    Rescheduled Special Meeting

    The firm has stated that its previously planned Special General Meeting of Shareholders, which was originally scheduled for May 20, 2025, has been rescheduled to May 23, 2025, in order to meet with transparency and regulatory obligations. By making this adjustment, stakeholders are guaranteed enough time to examine the most recent transaction facts.